BIOSTAR PHARM-B (02563) announced its interim results for the six months ended June 30, 2025. The company reported revenue of RMB 14.787 million, representing a decrease of 55.36% compared to the same period last year. Net loss amounted to RMB 54.041 million, which narrowed by 23.41% year-on-year. Basic loss per share was RMB 0.15.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.